Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 33

1.

Country recommendations on the inclusion of HPV vaccines in national immunization programmes among high-income countries, June 2006-January 2008.

Koulova A, Tsui J, Irwin K, Van Damme P, Biellik R, Aguado MT.

Vaccine. 2008 Dec 2;26(51):6529-41. doi: 10.1016/j.vaccine.2008.08.067. Review.

PMID:
18805453
2.

Prevalence of human papillomavirus in Indonesia: a population-based study in three regions.

Vet JN, de Boer MA, van den Akker BE, Siregar B, Lisnawati, Budiningsih S, Tyasmorowati D, Moestikaningsih, Cornain S, Peters AA, Fleuren GJ.

Br J Cancer. 2008 Jul 8;99(1):214-8.

3.

Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.

Goldie SJ, O'Shea M, Campos NG, Diaz M, Sweet S, Kim SY.

Vaccine. 2008 Jul 29;26(32):4080-93. doi: 10.1016/j.vaccine.2008.04.053. Epub 2008 May 15.

PMID:
18550229
4.

Age considerations when vaccinating against HPV.

Wright TC Jr, Huh WK, Monk BJ, Smith JS, Ault K, Herzog TJ.

Gynecol Oncol. 2008 May;109(2 Suppl):S40-7. doi: 10.1016/j.ygyno.2008.02.002. Review.

PMID:
18482558
5.

Rates of human papillomavirus vaccination, attitudes about vaccination, and human papillomavirus prevalence in young women.

Kahn JA, Rosenthal SL, Jin Y, Huang B, Namakydoust A, Zimet GD.

Obstet Gynecol. 2008 May;111(5):1103-10. doi: 10.1097/AOG.0b013e31817051fa.

PMID:
18448742
6.

Risk of female human papillomavirus acquisition associated with first male sex partner.

Winer RL, Feng Q, Hughes JP, O'Reilly S, Kiviat NB, Koutsky LA.

J Infect Dis. 2008 Jan 15;197(2):279-82. doi: 10.1086/524875.

7.

HPV and cervical cancer in the 2007 report.

WHO/ICO Information Centre on HPV and Cervical Cancer..

Vaccine. 2007 Nov 1;25 Suppl 3:C1-230. No abstract available.

PMID:
18068032
8.

Confirmatory real-time PCR assay for human papillomavirus (HPV) type 52 infection in anogenital specimens screened for HPV infection with the linear array HPV genotyping test.

Coutlée F, Rouleau D, Ghattas G, Hankins C, Vézina S, Coté P, Macleod J, de Pokomandy A, Money D, Walmsley S, Voyer H, Brassard P, Franco E.

J Clin Microbiol. 2007 Nov;45(11):3821-3. Epub 2007 Sep 26.

9.

Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial.

Hildesheim A, Herrero R, Wacholder S, Rodriguez AC, Solomon D, Bratti MC, Schiller JT, Gonzalez P, Dubin G, Porras C, Jimenez SE, Lowy DR; Costa Rican HPV Vaccine Trial Group..

JAMA. 2007 Aug 15;298(7):743-53.

PMID:
17699008
10.

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial.

Paavonen J, Jenkins D, Bosch FX, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter DL, Kitchener HC, Castellsague X, de Carvalho NS, Skinner SR, Harper DM, Hedrick JA, Jaisamrarn U, Limson GA, Dionne M, Quint W, Spiessens B, Peeters P, Struyf F, Wieting SL, Lehtinen MO, Dubin G; HPV PATRICIA study group..

Lancet. 2007 Jun 30;369(9580):2161-70. Erratum in: Lancet. 2007 Oct 20;370(9596):1414.

PMID:
17602732
11.

Sociodemographic factors associated with high-risk human papillomavirus infection.

Kahn JA, Lan D, Kahn RS.

Obstet Gynecol. 2007 Jul;110(1):87-95. Erratum in: Obstet Gynecol. 2007 Sep;110(3):713.

PMID:
17601901
12.

HPV type-specific risks of high-grade CIN during 4 years of follow-up: a population-based prospective study.

Naucler P, Ryd W, Törnberg S, Strand A, Wadell G, Hansson BG, Rylander E, Dillner J.

Br J Cancer. 2007 Jul 2;97(1):129-32. Epub 2007 Jun 5.

13.

Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.

Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GW, Ferris DG, Steben M, Bryan J, Taddeo FJ, Railkar R, Esser MT, Sings HL, Nelson M, Boslego J, Sattler C, Barr E, Koutsky LA; Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators..

N Engl J Med. 2007 May 10;356(19):1928-43.

14.

Why blacks do not take part in HIV vaccine trials.

Moutsiakis DL, Chin PN.

J Natl Med Assoc. 2007 Mar;99(3):254-7.

15.

Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).

Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER; Centers for Disease Control and Prevention (CDC).; Advisory Committee on Immunization Practices (ACIP)..

MMWR Recomm Rep. 2007 Mar 23;56(RR-2):1-24.

16.

Prevalence of HPV infection among females in the United States.

Dunne EF, Unger ER, Sternberg M, McQuillan G, Swan DC, Patel SS, Markowitz LE.

JAMA. 2007 Feb 28;297(8):813-9.

PMID:
17327523
17.

The distribution and differential risks of human papillomavirus genotypes in cervical preinvasive lesions: A Taiwan Cooperative Oncologic Group Study.

Chen CA, Liu CY, Chou HH, Chou CY, Ho CM, Twu NF, Kan YY, Chuang MH, Chu TY, Hsieh CY; Taiwan Cooperative Oncologic Group..

Int J Gynecol Cancer. 2006 Sep-Oct;16(5):1801-8.

PMID:
17009975
18.

Parents concerned about vaccine safety: Differences in race/ethnicity and attitudes.

Shui IM, Weintraub ES, Gust DA.

Am J Prev Med. 2006 Sep;31(3):244-51. Epub 2006 Jul 13.

PMID:
16905036
19.

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial.

Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, Jenkins D, Schuind A, Costa Clemens SA, Dubin G; HPV Vaccine Study group..

Lancet. 2006 Apr 15;367(9518):1247-55.

20.

HIV vaccine trial participation among ethnic minority communities: barriers, motivators, and implications for recruitment.

Newman PA, Duan N, Roberts KJ, Seiden D, Rudy ET, Swendeman D, Popova S.

J Acquir Immune Defic Syndr. 2006 Feb 1;41(2):210-7.

PMID:
16394854

Supplemental Content

Support Center